Cinven completes acquisition of Bioclinica

October 20, 2016

Cinven has today completed the acquisition of Bioclinica, a global provider of clinical trial services and technology to contract research organisations (CROs) and pharmaceutical companies, for an undisclosed consideration.

Cinven's healthcare team identified Bioclinica as a compelling investment opportunity given the team’s strong track record in the clinical trials sector and direct experience through its investment in Medpace, a leading CRO business. Bioclinica operates in a number of high growth areas to improve the efficiency and productivity of clinical trials. Bioclinica benefits from structural factors including as growing clinical trial activity, increased outsourcing and the adoption of clinical software services.

Bioclinica represents the first investment from Cinven's sixth fund.

For the latest Company news and information, follow Bioclinica on the blog at http://www.bioclinica.com/blog and on Twitter at http://twitter.com/bioclinica.

About Bioclinica

Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging and Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises an eClinical technology platform and professional services along with safety and regulatory solutions. Under the Global Clinical Research segment, Bioclinica offers a network of research sites, patient recruitment-retention services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia.
Learn more at www.bioclinica.com.